
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
17.7.2014
0:00
7:28
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
Weitere Episoden von „GRACEcast Lung Cancer Audio“



Verpasse keine Episode von “GRACEcast Lung Cancer Audio” und abonniere ihn in der kostenlosen GetPodcast App.








